VistaGen not 'a one product' company, says CEO
VistaGen Therapeutics (VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system diseases and disorders with high unmet need, including major depressive disorder, neuropathic pain, social anxiety disorder and suicidal ideation. In an exclusive interview with The Fly, the company's CEO Shawn Singh clarified possible misconceptions about VistaGen and its pipeline: "A key misconception is that we are a one-product, one-disease company. Nothing could be further from the truth. We have three novel, differentiated, patent-protected, clinical-stage product candidates, each of which, as is often the case with the evolution of CNS products, has therapeutic and thus commercial potential for treatment of multiple diseases and disorders in multiple markets where current treatments are inadequate at meeting the needs of millions of patients. We have several products and opportunities to explore many markets with each of them." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company.